Metabolic Syndrome and the Risk of Prostate Cancer

ownloade kground: Associations between metabolic syndrome (MetS) components and prostate cancer develophave not been studied comprehensively; results have been divergent. Using the National Cholesterol tion Program Adult Treatment panel III (NCEP) and International Diabetes Federation (IDF) definitions MetS, we investigated such associations taking competing risks of death into consideration. thods: In the prospective Uppsala Longitudinal Study of Adult Men of 2,322 Caucasian men with rs of follow-up baseline, MetS measurements at age 50 years were used. Cumulative incidence of prosncer and death with/without the MetS were calculated. Competing risk of dying was taken into t by calculating the conditional probability of prostate cancer with/without the MetS. ults: Two hundred and thirty-seven prostate cancers were identified. Prostate cancer probability by age rs with baseline MetS compared with without MetS was nonsignificantly higher [5.2 percent units ence interval (CI), −0.8% to 11.3%; NCEP); 2.7 percent units (CI, −2.7% to 8.0%; IDF)]; cumulative ine proportions of death was significantly higher [19.3 percent units (CI, 13.4-25.3%; NCEP); 15.3 percent CI, 9.5-21.1%; IDF)]; and conditional probability of prostate cancer considering death from other causes gnificantly higher [7.3 percent-units (CI, 0.2-14.5%); odds ratio of 1.64 (CI, 1.03-2.23; NCEP)] and noncantly higher [5.0 percent-units (CI, −1.6% to 11.6%); odds ratio of 1.43 (CI, 0.89-1.90; IDF]. clusions: The MetS by the NCEP definition is associated with prostate cancer, taking the competing early death from other causes into account. act: The results further highlight the public health effect of the increasing prevalence of MetS and the Imp importance of considering competing risks when studying risk factors for cancer. Cancer Epidemiol Biomarkers Prev; 19(8); 2088–96. ©2010 AACR.